Skip to main content
Jonathan Kaufman, MD, Oncology, Atlanta, GA

JonathanLKaufmanMD

Oncology • Atlanta, GA

Hematologic Oncology

Professor, Hematology and Medical Oncology, Winship Cancer Institute of Emory University

Join to view full profile

Dr. Kaufman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kaufman's full profile

Already have an account?

  • Office

    1365 Clifton Rd Ne
    Atlanta, GA 30322
    Phone+1 404-778-1900
    Fax+1 404-778-3260

Summary

  • Jonathan Kaufman, MD is an oncologist based in Atlanta, GA, with a subspecialty in hematologic oncology. He completed his fellowship and residency at Emory University School of Medicine after graduating from the Medical College of Georgia at Augusta University in 1999. Dr. Kaufman has extensive experience in treating conditions like AL amyloidosis, multiple myeloma and waldenstrom macroglobulinamia among others. He has multiple publications to his name, and he has led clinical trials as the Principal Investigator, including trials focusing on treatments for newly diagnosed and relapsed/refractory multiple myeloma.

Education & Training

  • Emory University School of Medicine
    Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2001 - 2005
  • Emory University School of Medicine
    Emory University School of MedicineResidency, Internal Medicine, 1999 - 2001
  • Medical College of Georgia at Augusta University
    Medical College of Georgia at Augusta UniversityClass of 1999

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2003 - 2025
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
    Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple ...
    Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
    Jonathan L. Kaufman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Challenges in Myeloma Therapy 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed ... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Efficacy and safety of daratumumab, lenalidomide, and dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Updated subgroup analysis of POLLUX based... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Join now to see all

Press Mentions

  • Jonathan Kaufman, MD, Talks Targeting BCL-2 with Venetoclax and Dexamethasone in R/R MM
    Jonathan Kaufman, MD, Talks Targeting BCL-2 with Venetoclax and Dexamethasone in R/R MMMay 12th, 2021

Professional Memberships

Dr. Jonathan Kaufman, Dr. Jonathan Kaufman, MD, Dr. J Kaufman, Dr. Jonathan L Kaufman